| Size | Price | Stock | Qty |
|---|---|---|---|
| 5mg |
|
||
| 10mg |
|
||
| 50mg |
|
||
| 100mg |
|
||
| 250mg | |||
| Other Sizes |
| Targets |
N,N-Diacetyl-Lys-D-Ala-DAla does not have a specific biological target as a drug. It is an oligopeptide used in biochemical research. The compound may be recognized by certain enzymes, such as peptidases, but it is not designed to interact with specific receptors or enzymes for therapeutic purposes. Its primary utility is as a research tool for studying peptide interactions, enzymatic activity, and protein biochemistry.
|
|---|---|
| ln Vitro |
In vitro, N,N-Diacetyl-Lys-D-Ala-DAla is used as a substrate in enzymatic assays to study the activity of peptidases and other enzymes that recognize D-amino acid-containing peptides. It may also be used in studies of peptide-protein interactions. The compound does not exhibit significant pharmacological activities such as receptor binding or enzyme inhibition. Its role in research is as a reagent for studying peptide chemistry and biochemistry.
|
| ln Vivo |
N,N-Diacetyl-Lys-D-Ala-DAla is not a pharmacologically active compound and therefore does not have defined in vivo activity as a therapeutic agent. It is an oligopeptide used in biochemical research. When administered to animals, it would likely be metabolized by peptidases to release its constituent amino acids. Its primary value remains in research, where it serves as a tool for studying peptide interactions, enzymatic activity, and protein biochemistry.
|
| Enzyme Assay |
In vitro enzyme assays for N,N-Diacetyl-Lys-D-Ala-DAla are typically designed to study the activity of peptidases or other enzymes that recognize D-amino acid-containing peptides. A standard protocol involves incubating the compound with an enzyme preparation in a suitable buffer. The hydrolysis of the peptide bonds releases amino acids, which can be quantified by HPLC or mass spectrometry. The progress of the reaction can be monitored, and kinetic parameters can be determined.
|
| Cell Assay |
In vitro cellular assays using N,N-Diacetyl-Lys-D-Ala-DAla are limited because the compound is primarily a research reagent. However, it can be used in cell culture studies to investigate peptide transport and metabolism. Cells are cultured in media supplemented with the compound, and its uptake and hydrolysis are monitored. The effects of the released amino acids on cellular metabolism can be assessed.
|
| Animal Protocol |
In vivo animal studies with N,N-Diacetyl-Lys-D-Ala-DAla are not typically conducted for therapeutic purposes. However, it may be used in metabolic studies to investigate the metabolism of D-amino acid-containing peptides. A typical protocol involves administration of the compound to rodents, followed by blood and tissue sampling to measure its levels and metabolites. These studies help to understand the metabolism of D-peptides.
|
| ADME/Pharmacokinetics |
As a small oligopeptide, N,N-Diacetyl-Lys-D-Ala-DAla is expected to be rapidly metabolized in the body. Its pharmacokinetic properties are characteristic of small peptides, with rapid clearance and short half-life. Detailed pharmacokinetic data are not typically reported, as the compound is used primarily as a research reagent rather than a drug candidate.
|
| Toxicity/Toxicokinetics |
N,N-Diacetyl-Lys-D-Ala-DAla is generally considered to have low toxicity, consistent with its use as a research reagent. It is a peptide composed of naturally occurring amino acids. Standard laboratory safety precautions, including the use of personal protective equipment, are recommended. No significant systemic toxicity is anticipated at typical research doses.
|
| References | |
| Additional Infomation |
N,N-Diacetyl-Lys-D-Ala-DAla (Ac-Lys-D-Ala-D-Ala-OH, CAS 28845-97-8) is an oligopeptide composed of a lysine residue with two acetyl groups and two D-alanine residues. Its molecular formula is C₁₄H₂₆N₄O₅ and its molecular weight is approximately 330.19 g/mol. It may be utilized in a variety of biochemical studies. It is a synthetic peptide used in research applications. It is intended for research use only.
|
| Molecular Formula |
C14H26N4O5
|
|---|---|
| Molecular Weight |
330.38004
|
| Exact Mass |
330.19
|
| CAS # |
28845-97-8
|
| PubChem CID |
3082292
|
| Appearance |
Typically exists as solid at room temperature
|
| Density |
1.2±0.1 g/cm3
|
| Boiling Point |
731.1±60.0 °C at 760 mmHg
|
| Flash Point |
396.0±32.9 °C
|
| Vapour Pressure |
0.0±5.2 mmHg at 25°C
|
| Index of Refraction |
1.510
|
| LogP |
-1.53
|
| Hydrogen Bond Donor Count |
5
|
| Hydrogen Bond Acceptor Count |
6
|
| Rotatable Bond Count |
10
|
| Heavy Atom Count |
23
|
| Complexity |
441
|
| Defined Atom Stereocenter Count |
3
|
| SMILES |
C[C@@H](NC([C@@H](NC(C)=O)CCCCN)=O)C(N[C@@H](C(O)=O)C)=O
|
| InChi Key |
GMSXMADYKTYBCP-KKZNHRDASA-N
|
| InChi Code |
InChI=1S/C14H26N4O5/c1-8(12(20)17-9(2)14(22)23)16-13(21)11(18-10(3)19)6-4-5-7-15/h8-9,11H,4-7,15H2,1-3H3,(H,16,21)(H,17,20)(H,18,19)(H,22,23)/t8-,9-,11+/m1/s1
|
| Chemical Name |
(2R)-2-[[(2R)-2-[[(2S)-2-acetamido-6-aminohexanoyl]amino]propanoyl]amino]propanoic acid
|
| HS Tariff Code |
2934.99.9001
|
| Storage |
Powder -20°C 3 years 4°C 2 years In solvent -80°C 6 months -20°C 1 month |
| Shipping Condition |
Room temperature (This product is stable at ambient temperature for a few days during ordinary shipping and time spent in Customs)
|
| Solubility (In Vitro) |
May dissolve in DMSO (in most cases), if not, try other solvents such as H2O, Ethanol, or DMF with a minute amount of products to avoid loss of samples
|
|---|---|
| Solubility (In Vivo) |
Note: Listed below are some common formulations that may be used to formulate products with low water solubility (e.g. < 1 mg/mL), you may test these formulations using a minute amount of products to avoid loss of samples.
Injection Formulations
Injection Formulation 1: DMSO : Tween 80： Saline = 10 : 5 : 85 (i.e. 100 μL DMSO stock solution → 50 μL Tween 80 → 850 μL Saline)(e.g. IP/IV/IM/SC) *Preparation of saline: Dissolve 0.9 g of sodium chloride in 100 mL ddH ₂ O to obtain a clear solution. Injection Formulation 2: DMSO : PEG300 ：Tween 80 : Saline = 10 : 40 : 5 : 45 (i.e. 100 μL DMSO → 400 μLPEG300 → 50 μL Tween 80 → 450 μL Saline) Injection Formulation 3: DMSO : Corn oil = 10 : 90 (i.e. 100 μL DMSO → 900 μL Corn oil) Example: Take the Injection Formulation 3 (DMSO : Corn oil = 10 : 90) as an example, if 1 mL of 2.5 mg/mL working solution is to be prepared, you can take 100 μL 25 mg/mL DMSO stock solution and add to 900 μL corn oil, mix well to obtain a clear or suspension solution (2.5 mg/mL, ready for use in animals). View More
Injection Formulation 4: DMSO : 20% SBE-β-CD in saline = 10 : 90 [i.e. 100 μL DMSO → 900 μL (20% SBE-β-CD in saline)] Oral Formulations
Oral Formulation 1: Suspend in 0.5% CMC Na (carboxymethylcellulose sodium) Oral Formulation 2: Suspend in 0.5% Carboxymethyl cellulose Example: Take the Oral Formulation 1 (Suspend in 0.5% CMC Na) as an example, if 100 mL of 2.5 mg/mL working solution is to be prepared, you can first prepare 0.5% CMC Na solution by measuring 0.5 g CMC Na and dissolve it in 100 mL ddH2O to obtain a clear solution; then add 250 mg of the product to 100 mL 0.5% CMC Na solution, to make the suspension solution (2.5 mg/mL, ready for use in animals). View More
Oral Formulation 3: Dissolved in PEG400 (Please use freshly prepared in vivo formulations for optimal results.) |
| Preparing Stock Solutions | 1 mg | 5 mg | 10 mg | |
| 1 mM | 3.0268 mL | 15.1341 mL | 30.2682 mL | |
| 5 mM | 0.6054 mL | 3.0268 mL | 6.0536 mL | |
| 10 mM | 0.3027 mL | 1.5134 mL | 3.0268 mL |
*Note: Please select an appropriate solvent for the preparation of stock solution based on your experiment needs. For most products, DMSO can be used for preparing stock solutions (e.g. 5 mM, 10 mM, or 20 mM concentration); some products with high aqueous solubility may be dissolved in water directly. Solubility information is available at the above Solubility Data section. Once the stock solution is prepared, aliquot it to routine usage volumes and store at -20°C or -80°C. Avoid repeated freeze and thaw cycles.
Calculation results
Working concentration： mg/mL；
Method for preparing DMSO stock solution： mg drug pre-dissolved in μL DMSO (stock solution concentration mg/mL). Please contact us first if the concentration exceeds the DMSO solubility of the batch of drug.
Method for preparing in vivo formulation:：Take μL DMSO stock solution, next add μL PEG300, mix and clarify, next addμL Tween 80, mix and clarify, next add μL ddH2O，mix and clarify.
(1) Please be sure that the solution is clear before the addition of next solvent. Dissolution methods like vortex, ultrasound or warming and heat may be used to aid dissolving.
(2) Be sure to add the solvent(s) in order.
Products are for research use only; We do not sell to patients
Copyright 2020 InvivoChem LLC | All Rights Reserved
